EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Design, Synthesis, In Vitro and In Silico Evaluation of Triazole–Benzimidazole Hybrid Derivatives as Potential Inhibitors of EGFR, EGFR-L858R, and EGFR-L858R/T790M

Harun Uslu iD, Arzu Hıdır, Esra Yumuşak, Derya Osmaniye iD, Bünyamin Göktaş iD, Yusuf Özkay iD, Zafer Asım Kaplancıklı iD

Molecules · 2026

DOI: 10.3390/molecules31193433 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecules, 2026. Verfasst von Harun Uslu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Fırat University, 23119 Elazığ, Türkiye. Hauptthemen laut MEDLINE: ErbB Receptors, Triazoles, Benzimidazoles, Drug Design. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fırat University, Firat University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Epidermal growth factor receptor (EGFR) has become one of the most important molecular targets for the development of anticancer agents because of its critical role in regulating cell proliferation, differentiation, and survival. In the present study, a novel series of benzimidazole–triazole derivatives were designed by incorporating pharmacophoric features of clinically used EGFR inhibitors, synthesized, characterized, and evaluated for their anticancer potential. Cytotoxicity studies against the A549 lung cancer cell line identified 2-((4-Ethyl-5-(2-(4-hydroxyphenyl)-1H-benzo[d]imidazol-6-yl)-4H-1,2,4-triazol-3-yl)thio)-N-methylacetamide, 2-((4-Ethyl-5-(2-(4-hydroxyphenyl)-1H-benzo[d]imidazol-6-yl)-4H-1,2,4-triazol-3-yl)thio)-N-(hydroxymethyl)acetamide, 2-((4-Ethyl-5-(2-(4-hydroxyphenyl)-1H-benzo[d]imidazol-6-yl)-4H-1,2,4-triazol-3-yl)thio)-N-methoxy-N-methylacetamide, and 2-((4-Ethyl-5-(2-(4-hydroxyphenyl)-1H-benzo[d]imidazol-6-yl)-4H-1,2,4-triazol-3-yl)thio)-N-phenylacetamide as active derivatives, with compound 5a exhibiting the highest antiproliferative activity (IC50 = 6.014 ± 0.758 µM), and relatively low cytotoxicity toward NIH/3T3 cells. Based on these findings, 2-((4-Ethyl-5-(2-(4-hydroxyphenyl)-1H-benzo[d]imidazol-6-yl)-4H-1,2,4-triazol-3-yl)thio)-N-methylacetamide was further evaluated against EGFR and its clinically relevant mutant forms, EGFR-L858R and EGFR-L858R/T790M. Retrospective in silico ADME analysis indicated that the synthesized compounds generally possessed favorable drug-like properties, with 2-((4-Ethyl-5-(2-(4-hydroxyphenyl)-1H-benzo[d]imidazol-6-yl)-4H-1,2,4-triazol-3-yl)thio)-N-methylacetamide showing the most favorable overall drug-likeness profile among the series. Molecular docking and molecular dynamics studies revealed that compound 2-((4-Ethyl-5-(2-(4-hydroxyphenyl)-1H-benzo[d]imidazol-6-yl)-4H-1,2,4-triazol-3-yl)thio)-N-methylacetamide formed stable interactions with key residues in the ATP-binding site of unmutated EGFR, supporting the in vitro inhibition results. Overall, synthesized benzimidazole–triazole derivatives may be promising precursor compounds for the development of novel EGFR inhibitors, particularly against unmutated EGFR cancer cells.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ErbB ReceptorsTriazolesBenzimidazolesDrug DesignAntineoplastic AgentsProtein Kinase InhibitorsHumansMolecular Docking SimulationStructure-Activity RelationshipCell ProliferationCell Line, TumorAnimalsMutationA549 CellsMiceMolecular Structure

Stichwörter der Autor:innen

ADMEEGFR inhibitorsbenzimidazolemolecular dockingmolecular dynamicsmutant EGFRtriazole

Substanzen

ErbB ReceptorsTriazolesBenzimidazolesEGFR protein, humanAntineoplastic AgentsProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Fırat University, 23119 Elazığ, Türkiye.
  • Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Anadolu University, 26470 Eskişehir, Türkiye.
  • Department of Pharmaceutical Chemistry, The Institute of Graduate Education, Anadolu University, 26470 Eskişehir, Türkiye.
  • Faculty of Pharmacy, Anadolu University, 26470 Eskişehir, Türkiye.
  • Central Research Laboratory, Faculty of Pharmacy, Anadolu University, 26470 Eskişehir, Türkiye.

ORCID-Profile: Harun Uslu, Derya Osmaniye, Bünyamin Göktaş, Yusuf Özkay, Zafer Asım Kaplancıklı

Förderung

  • Fırat University
  • Firat University

Zitieren

APA

Uslu, H., Hıdır, A., Yumuşak, E., Osmaniye, D., Göktaş, B., Özkay, Y., & Kaplancıklı, Z. A. (2026). Design, Synthesis, In Vitro and In Silico Evaluation of Triazole–Benzimidazole Hybrid Derivatives as Potential Inhibitors of EGFR, EGFR-L858R, and EGFR-L858R/T790M. Molecules. https://doi.org/10.3390/molecules31193433

Vancouver

Uslu H, Hıdır A, Yumuşak E, Osmaniye D, Göktaş B, Özkay Y, et al. Design, Synthesis, In Vitro and In Silico Evaluation of Triazole–Benzimidazole Hybrid Derivatives as Potential Inhibitors of EGFR, EGFR-L858R, and EGFR-L858R/T790M. Molecules. 2026. doi:10.3390/molecules31193433

BibTeX
@article{Uslu2026,
  author = {Uslu, Harun and Hıdır, Arzu and Yumuşak, Esra and Osmaniye, Derya and Göktaş, Bünyamin and Özkay, Yusuf and Kaplancıklı, Zafer Asım},
  title = {Design, Synthesis, In Vitro and In Silico Evaluation of Triazole–Benzimidazole Hybrid Derivatives as Potential Inhibitors of EGFR, EGFR-L858R, and EGFR-L858R/T790M},
  journal = {Molecules},
  year = {2026},
  doi = {10.3390/molecules31193433}
}
Kostenlos starten →